A small desk with a strict standard.
Aminoscope is an independent research desk covering peptides, GLP-1 medications, and longevity therapeutics. We exist because the gap between what the trials say and what the internet says about these molecules is enormous — and consequential.
Aminoscope is published by MEAS Partners, LLC. Our writers publish under consistent pen names — a common practice in health and science journalism — so that the work is judged on its sourcing rather than on personality. Bylines are stable: the same name always means the same writer, and every claim is anchored to a citation you can check yourself.
Medical and scientific accuracy is verified against primary sources before anything is published. For clinical content we are building a panel of licensed reviewers; review status is stated honestly on each piece, and we never attach credentials we cannot stand behind.
The desk
Julian Roth
Research & dataTrials, effect sizes, and the primary literature. Reads the methods section so you don't have to.
Nadia Feldman
Practical & accessCost, coverage, side-effect timelines, and what a therapy actually looks like in real life.
Priya Anand
Pharmacology & mechanismsHow these molecules actually work — receptors, half-lives, interactions — and where the mechanism story outruns the evidence.
Theo Lindqvist
Peptides & longevityThe peptide and healthspan frontier, graded honestly: what has human data, what is preclinical, and what is still just a promise.
Read more about how we work in our methodology and disclosures.